LIXTE Biotechnology (NASDAQ:LIXT) has announced that, in collaboration with the Netherlands Cancer Institute (NKI), the first patient has been dosed in a new clinical trial of LUXTE’s lead compound, LB-100, for the treatment of unresponsive metastatic colorectal cancer. The study is supported by F. Hoffmann-La Roche who is providing Tecentriq, a PDL1 inhibitor.
LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. The company states that, based on extensive published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
“Our objective with this trial is to bring immunotherapy as an effective treatment option to approximately 85 percent of all colorectal cancer patients, who thus far have not been responsive to traditional protocols,” said Neeltje Steeghs, M.D., Ph.D., medical oncologist at NKI.
In a statement, Bas van der Baan, LIXTE’s Chief Executive Officer, said, “We are pleased to begin this important trial, which is being funded by Roche. This is the second recent clinical trial combining LB-100 with immunotherapy that is funded by a major pharmaceutical company, following the start of a clinical trial earlier this year with GSK for treatment of clear cell ovarian cancer.”
